Oxford Sciences Innovation Archives

News and Trends 17 Feb 2020

UK Biotech Closes €50M Series A for GPCR Drug Discovery

Oxford-based OMass Therapeutics has extended its Series A round by €33M to fund the spectrometry-assisted development of drugs targeting G protein-coupled receptors. OMass Therapeutics’s Series A initially raised €17M in late 2018. The new funds bring this up to €50M (£41.5M). Investors in the most recent fundraise included the UK VC firm Syncona — which […]

February 17, 2020 - 2 minutesmins - By Jonathan Smith

More News! 7 Oct 2019

UK Biotech Launches with €30M Series A to Treat Autoimmune Disease

MiroBio has spun out of the University of Oxford with a Series A round of €30M (£27M) to develop treatments for autoimmune diseases that don’t disrupt the immune system as a whole. The big Series A round accompanying MiroBio’s launch was co-led by the university’s investor partner Oxford Sciences Innovation and the US investor Samsara […]

October 7, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 22 Jun 2017

LAB282 Awards Second Funding Round to 5 Academic Projects at Oxford

Evotec and the University of Oxford have announced the academic projects that will receive a financial award to push them towards launching spin-outs. LAB282 is a partnership between the German biotech Evotec, Oxford University Innovation and Oxford Sciences Innovation, the University’s venture fund manager. Set up with the aim to bridge academia and industry in life sciences, LAB282 […]

June 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Nov 2016

Evotec chooses Oxford as Proving Ground for Academia-Industry Bridge

The German CRO has struck a deal with the University of Oxford to test a model framework for bringing academic research to the clinic faster. Evotec started out as a service provider in Hamburg, but thanks to former CEO Jörn Aldag, it has blossomed into a company that specializes in transforming newly discovered therapies into […]

November 10, 2016 - 3 minutesmins - By Evelyn Warner

oxstem regenerative medicine stem cell leukemia

News and Trends 12 May 2016

Oxford Spin-Out Raises Record €21M to Re-Program Stem Cells

OxStem’s strategy for stem cells therapy inside the body could have a big impact in regenerative medicine – and it has raised €21.4M, a record for a UK spin-out. A spin-out of Oxford University, OxStem is developing cell programming therapies that could treat a range of usually age-related conditions – dementia, heart failure, macular degeneration, […]

May 12, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 1 Oct 2015

Neil Woodford’s Latest €25M UK Biotech pay-out is to AMO Pharma

As we already well know, Neil Woodford is an Economist investor listed as one of the most influential figures in the European biotech industry. From London (UK), his private equity firm Woodford Patient Capital Trust is now planning to dish out €25M to AMO Pharma, to further their phase II pipeline therapies for CNS disorders such […]

October 1, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Aug 2015

It’s raining cash, Woodford invested more than 75% of its mega €1.1Bn Biotech fund

Cash is floating into Biotech like never before, in the US as well as in Europe. And Woodford just announced he invested over 75% of the total money he raised, so over €800M. Let’s have a look at where the money went into. Neil Woodford is a legendary British Biotech investor who opened a new […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us